Skip to main content
. 2022 Mar 11;76:103486. doi: 10.1016/j.amsu.2022.103486

Table 2.

Demographics of patients with myocarditis and pericarditis after COVID-19 vaccine.

Sr No Domain Author, Year Country reported Number of patients Age(years) Gender M/F Medical History Type of Vaccine administered Myocarditis/Pericarditis Time between vaccine administration and development of myocarditis/pericarditis
1 Case report Cimaglia et al. (2021) [29] Portugal 1 24, Male E-cigarette smoking Pfizer-BioNTech Myocarditis 60 h after second dose
2 Case report Nguyen et al.(2021) [48] England 1 20, Male Not significant Moderna Myocarditis 12 h after first dose
3 Case report Watkins et al. (2021) [14] USA 1 20, Male COVID+, Tobacco+ Pfizer-BioNTech Myocarditis 48 h after second dose
4 Case series Vidula et al. (2021) [44] USA 5 Patient-No-1 19, Male, Not significant Pfizer-BioNTech Myocarditis 4 days after second dose
Patient-No-2 18, Male Not significant Moderna Myocarditis 24 h after second dose
Patient-No-3 60, Female Stress cardiopathy Pfizer-BioNTech Stress Cardiomyopathy 4 days after second dose
Patient-No-4 21, Female Not significant Pfizer-BioNTech Pericarditis 3 weeks after first dose
Patient-No-5 61, female HTN+ Pfizer-BioNTech Pericarditis 4 weeks after second dose
5 Case report Albert et al. (2021) [43] USA 1 24, Male Not significant Moderna Myocarditis 4 days after second dose
6 Case series Shaw et al. (2021) [32] USA 4 Patient,No,1 24, Male Not significant Pfizer-BioNTech Myocarditis 4 days after second dose
Patient-No-2 31, Female A history of confirmed COVID+ 7 months ago Moderna Myocarditis 25 days after first dose
Patient-No-3 16, Male COVID+ Pfizer-BioNTech Myocarditis 4 days after first dose
Patient-No-4 17, Female Not Significant Pfizer-BioNTech Myocarditis 2 days after second dose
7 Case report Habib et al. (2021) [28] Qatar 1 37, Male Ex-smoker, alcoholic, HTN + ve Pfizer-BioNTech Myocarditis 3 days after second dose
8 Case series Abbate et al. (2021) [34] USA 2 Patient-No- 1 27, Male Downs syndrome + ve, Pfizer-BioNTech Fulminant pericarditis 2 days after second dose
Patient-No-2 34, Female Not significant Pfizer-BioNTech Fulminant myocarditis 9 days after first dose
9 Case series Mouch et al. (2021) [19] Israel 6 Patient 1 24, Male Not significant Pfizer-BioNTech Myocarditis 72 h after second dose
Patient-No-2 20, Male Not significant Pfizer-BioNTech Myocarditis 24 h after second dose
Patient-No-3 29, Male Not significant Pfizer-BioNTech Myocarditis 48 h after second dose
Patient-No-4 45, Male Not significant Pfizer-BioNTech Myocarditis 16 days after first dose
Patient-No-5 16, Male Not significant Pfizer-BioNTech Myocarditis 24 h after second dose
Patient-No-6 17, Male Not significant Pfizer-BioNTech Myo-pericarditis 72 h after second dose
10 Case report Ammirati et al.(2021) [45] Italy 1 56, Male COVID + ve Pfizer-BioNTech Myocarditis 3 days after second dose
11 Case report Cereda et al. (2021) [51] Italy 1 21, Male Not significant Pfizer-BioNTech Myocarditis 30 h after second dose
12 Case series Chamling et al. (2021) [21] Germany 3 Patient-No-1 68, Female Tobacco+, CVD+ AstraZeneca Myocarditis 24 h after first dose
Patient-No-2 25, Male Smoker + ve, Pfizer-BioNTech Myocarditis 10 days after first dose
Patient-No-3 20, Male Not significant Pfizer-BioNTech Myocarditis 3 days after second dose
13 Case report D'Angelo et al.(2021) [52] Italy 1 30, Male Not significant Pfizer-BioNTech Myocarditis 72 h after second dose
14 Case report Deb et al. (2021) [18] USA 1 67, Male HTN+, T2DM, Hyperlipidemia, CAD with CABG, CHD, COPD, GERD Moderna Myocarditis 6 h after second dose
15 Case series Dickey et al. (2021) [30] USA 6 Patient 1 Male (35–40 year) Not significant Pfizer-BioNTech Myocarditis 4 days after second dose
Patient 2 Male (16–20 year) Not significant Pfizer-BioNTech Myocarditis 3 days after second dose
Patient 3 Male (20–25 year) Not significant Moderna Myocarditis 4 days after second dose
Patient 4 Male (20–25 year) Not significant Pfizer-BioNTech Myocarditis 2 days after second dose
Patient 5 Male (16–20) year Not significant Pfizer-BioNTech Myocarditis 4 days after second dose
Patient 6 Male (16–20) year Not significant Pfizer-BioNTech Myocarditis 3 days after second dose
16 Case report Ehrlich et al. (2021) [36] Germany 1 40, Male Not significant Pfizer-BioNTech Myocarditis 2 day after first dose
17 Case report Hasnie et al. (2021) [39] USA 1 22, Male COVID + ve Moderna Perimyocarditis 3 days after first dose
18 Case series Hudson et al. (2021) [33] USA 2 Patient 1 24, Male Not significant Pfizer-BioNTech Myopericarditis 3 days after second dose
Patient 2 22, Male Not significant Pfizer-BioNTech Myopericarditis 12 h after second dose
19 Case series Larson et al. (2021) [17] Italy 8 Patient no 1 22, Male Not significant Moderna Myocarditis 3 days after second dose
Patient no 2 31, Male Not significant Moderna Myocarditis 3 days after second dose
Patient no 3 40, Male COVID + ve, Pfizer-BioNTech Myocarditis 2 days after first dose
Patient no 4 56, Male Not significant Pfizer-BioNTech Myocarditis 3 days after second dose
Patient 5 26, Male COVID + ve Pfizer-BioNTech Myocarditis 3 days after second dose
Patient 6 35, Male Not significant Pfizer-BioNTech Myocarditis 2 days after second dose
Patient 7 21, Male Not significant Pfizer-BioNTech Myocarditis 4 days after second dose
Patient 8 22, Male Not significant Pfizer-BioNTech Myocarditis 2 days after second dose
20 Case Report Khogali et al. . 2021 [46] Qatar 1 29, female CKD since birth and a background of food allergy Moderna Perimyocarditis 10 days after second dose
21 Case Report Kim et al. . 2021 [16] Korea 1 24, male Not significant Pfizer-BioNTech Myocarditis 1 day after second dose
22 Case Series King et al. . 2021 [23] USA 4 Patient No 1 23, Female Not significant Moderna Myocarditis 5 days after second dose
Patient No 2 20, Male Not significant Moderna Myocarditis 2 days after second dose
Patient No 3 29, Male Not significant Moderna Myocarditis 4 days after second dose
Patient No 4 30, Male Not significant Pfizer-BioNTech Myocarditis 4 days after second dose
23 Case series Koizumi et al. . 2021 [35] Japan 2 22, Male Not significant Moderna Myocarditis 2 days after second dose
27, Male Not significant Moderna Myocarditis 3 days after second dose
24 Case series Mansour et al. . 2021 [15] USA 2 Patient No 1 25, Male Not significant Moderna Myocarditis 1 day after second dose
Patient No 2 21, Female CVDz + ve(long QT syndrome in siblings) Moderna Myocarditis 2 days after second dose
25 Case Report Matta et al. . 2021 [42] USA 1 27, Male Not significant Pfizer-BioNTech Myocarditis 3 days after second dose
26 Case Report Muthukumar et al. . 2021 [27] USA 1 52, Male CVD + ve Moderna Myocarditis 3 days after second dose
27 Case Report Nassar et al. . 2021 [26] USA 1 70, Female history of multiple sclerosis Janssen COVID-19 vaccine Myocarditis after two days
28 Case Series Nevet et al. . 2021 [38] Israel 3 20, 29, and 24 years old men Not significant Pfizer-BioNTech Myocarditis 2 days after second dose
29 Case series Patel et al., 2021 [31] USA Five (5) Patient no.1 22, Male History of ADHD+, Pfizer-BioNTech Acute myopericarditis 2 days after second dose
Patient no2 19, Male History of asthma+ Pfizer-BioNTech Myopericarditis 1 day after second dose
Patient no.3 25, Male Not significant Moderna Acute myopericarditis 3 days after second dose
Patient no.4 37, Male Not significant Pfizer-BioNTech Acute myocarditis 2 days after second dose
Patient no.5 20, Male Not significant Pfizer-BioNTech Acute myocarditis 3 days after second dose
30 Case series Rosner et al., 2021 [2] USA Seven (7) Patient no.1 28, Male Not signficant Janssen (Ad.26.COV2.S) Acute myocarditis 5 days after administration of dose
Patient no.2 39, Male Not signficant Pfizer-BioNTech Acute myocarditis 3 days after second dose
Patient no.3 39, Male Not signficant Moderna Acute myocarditis 4 days after first dose
Patient no.4 24, Male Not signficant Pfizer-BioNTech Acute myocarditis 7 days after second dose
Patient no.5 19, Male Not signficant Pfizer-BioNTech Acute myocarditis 2 days after second dose
Patient no.6 20, Male, COVID + history Pfizer-BioNTech Acute myocarditis 3 days after second dose
Patient no. 7 23, Male COVID + history Pfizer-BioNTech Acute myocarditis 3 days after second dose
31 Case report Singh et al., 2021 [40] USA One (1) 24, Male Ocassional alcoholic Pfizer-BioNTech Acute myocarditis 3 days after second dose
32 Case report Sokolska et al., 2021 [20] Poland One (1) 21, Male Asthma in childhood, history of appendectomy, pollen and pet allergy mRNA COVID-19 vaccination (Comirnaty, Pfizer) Acute myocarditis 3 days after first dose
33 Case series Starekova et al., 2021 [25] USA Five (5) Patient no.1 21, Male Not signficant Pfizer-BioNTech Acute myocarditis 2 days after second dose
Patient no2 32, Female Not signficant Pfizer-BioNTech Acute myocarditis 3 days after second dose
Patient no.3 17, Male Not significant Pfizer-BioNTech Acute myocarditis 2 days after second dose
Patient no.4 18, Male Not significant Moderna Acute myocarditis 3 days after second dose
Patient no.5 38, Male Not significant Moderna Acute myocarditis 3 days after second dose
34 Case report Tailor et al., 2021 [47] USA One (1) 44, Male Former smoker, Drug history: Albuterol, Salmetrol-fluticasone Moderna Acute myocarditis 4 days after second dose
35 Case report Ujueta et al., 2021 [37] USA One (1) 62, Female Medical history significant for melanoma status post-surgical resection and treatment with Pembrolizumab over one year prior as well as essential thrombocytosis currently receiving treatment with Anagrelide Janssen Johnson & John-son (Ad.26.COV2.S) Lypmhohistiocytic myocarditis 4 days after vaccine
36 Case series Verma et al., 2021 [41] USA Two (2) Patient no.1 45, Female Not significant Pfizer-BioNTech Fulminant myocarditis 10 days after first dose
Patient no2 42, Male Not signficant Moderna Fulminant myocarditis 14 days after second dose
37 Case report Williams et al., 2021 [50] USA One (1) 34, Male Not signficant Moderna Perimyocarditis 1 day after second dose
38 Case series Levin et al.(2021) [24] Israel 7 Patient 1 20, Male ADHD Pfizer-BioNTech Myocarditis 1 day after second dose
Patient no 2 19, Male Celiac disease Pfizer-BioNTech Myocarditis 1 day after second dose
Patient No-3 19, male Allergic asthma Pfizer-BioNTech Myocarditis 1 day after second dose
Patient No-4 22, Male Not significant Pfizer-BioNTech Myocarditis 5 day after second dose
Patient No-5 24, Male Not significant Pfizer-BioNTech Myocarditis 2 days after second dose
Patient-No-6 21, Male Myocarditis 5 years ago Pfizer-BioNTech Myocarditis 5 days after second dose
Patient-No-7 18, Male Not significant Pfizer-BioNTech Myocarditis 2 days after second dose
39 Case report Patrignani et al. (2021) [22] Italy 1 56, Male COVID+ 5 months ago Pfizer-BioNTech Myocarditis 4 days after first dose
40 Case report Sulemankhil et al.(2021) [49] USA 1 33, Male History of asthma and sleep apnea Janssen Johnson & John-son (Ad.26.COV2.S) Myocarditis 24 h after vaccination
41 Case report Garcia et al. (2021) [13] Spain 1 39, Male History of asthma, autoimmune hypothyroidism, chronic atrophic gastritis, an isolated episode of atrial fibrillation, and recurrent spontaneous pneumothorax with left apical lobectomy Pfizer-BioNTech Pericarditis 6 h after second dose

COPD: Chronic Obstructive Pulmonary Disease, CKD: Chronic Kidney Disease, CVD: Cardiovascular Disease, CAD: Coronary Artery Disease, ADHD: Attention Deficit Hyperactivity Disorder, GERD: Gastroesophageal Reflux Disease, COVID: Coronavirus Disease, CHD: Coronary Heart Disease, CABG: Coronary Artery Bypass Grafting, HTN: Hypertension, T2DM: type 2 Diabetes Mellitus.